Don't miss out! Stay informed with our latest updates! Sign up for email alerts here: https://bit.ly/3R6wnNH #XBIO #Oncology #SolidTumors #DNase
Xenetic Biosciences, Inc.
Biotechnology Research
Framingham, MA 875 followers
Enhancing Lives with Transformative Therapies
About us
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
- Website
-
http://www.xeneticbio.com/
External link for Xenetic Biosciences, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Framingham, MA
- Type
- Public Company
Locations
-
Primary
Get directions
40 Speen Street
Suite 102
Framingham, MA 01701, US
Employees at Xenetic Biosciences, Inc.
-
Reid Bissonnette
-
Jim Parslow, CPA, MBA
Strategic Chief Financial Officer / Public / Private / IPO / Capital Raising / Mergers & Acquisitions
-
Grigory Borisenko
Member Board Of Directors at Xenetic Biosciences, Inc. (Framingham, MA, US)
-
Gregory Gregoriadis, PhD, DSc
Founder, Xenetic Biosciences Inc.
Updates
-
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma https://bit.ly/3FGQpM1 #Oncology #SolidTumors #DNase
-
#PancreaticCancer is one of the most challenging indications in oncology, with a low survival rate and limited treatment options. Advances in research are critical to improving outcomes for patients facing this devastating disease. #XBIO #Oncology #SolidTumors #DNase
-
-
#InCaseYouMissedIt: Dr. Reid Bissonnette discussed the Company's recently announced extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform in a recent "What This Means" segment. Catch up here: https://bit.ly/4iotrYc #XBIO #Oncology #SolidTumors #DNase
-
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results https://bit.ly/41ymME5 #Oncology #SolidTumors #DNase
-
We are advancing a proprietary technology platform designed to enhance the effectiveness of immunotherapies, offering new possibilities for treating a range of cancers and improving patient outcomes. #XBIO #Oncology #SolidTumors #DNase
-
-
Review our latest corporate presentation to gain valuable insights and learn more about the advancements at #XBIO. https://bit.ly/4h8THEL #Oncology #SolidTumors #DNase
-
-
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses https://bit.ly/4huHri3 #DNase #Oncology
-
We believe in the power of partnership and collaboration to drive transformative advancements. If you're interested in partnering, reach out to info@xeneticbio.com. #XBIO #Oncology #SolidTumors #DNase
-
-
We are excited to announce that Dr. Alexey Stepanov will be presenting at the SITC Spring Scientific 2025 Cell Therapy Meeting on March 12 at 5:10 PM PT. See you there! #XBIO #Oncology #SolidTumors #DNase https://bit.ly/41jApGQ
-